biogen felzartamab - Search News

Biogen, felzartamab and TRANSCEND trial

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary membranous nephropathy, in 2025.

Clinical Trials Arena on MSN · 1d

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Pharmabiz · 15h

Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST]

Zacks Investment Research on M… · 1d

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR).

Markets Insider · 2d

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a

Biogen announces initiation of dosing in TRANSCEND

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

pharmaphorum1d

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Seeking Alpha29d

Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings

Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...

Nasdaq21d

Biogen Stock Is Mutating Into a Value Play

Biogen Inc. (NASDAQ ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the race really that we are ...

The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results